Table 1|.
Characteristics of patients in the study
| Characteristic | Total patients (n = 1,479) | Training set (n = 1,184) | Test set (n = 295) |
|---|---|---|---|
| Sex, n (%) | |||
| Female | 668 (45.17) | 529 (44.68) | 139 (47.12) |
| Male | 811 (54.83) | 655 (55.32) | 156 (52.88) |
| Age, median, years (IQR) | 64 (55–71) | 64 (55–71) | 64 (55–72) |
| Cancer type, n (%) | |||
| NSCLC | 538 (36.38) | 430 (36.32) | 108 (36.61) |
| Melanoma | 186 (12.58) | 149 (12.58) | 37 (12.54) |
| Renal | 91 (6.15) | 73 (6.17) | 18 (6.10) |
| Bladder | 82 (5.54) | 66 (5.57) | 16 (5.42) |
| Head and neck | 69 (4.67) | 55 (4.65) | 14 (4.75) |
| Sarcoma | 67 (4.53) | 54 (4.56) | 13 (4.41) |
| Endometrial | 65 (4.39) | 52 (4.39) | 13 (4.41) |
| Gastric | 64 (4.33) | 51 (4.31) | 13 (4.41) |
| Hepatobiliary | 52 (3.52) | 42 (3.55) | 10 (3.39) |
| SCLC | 50 (3.38) | 40 (3.38) | 10 (3.39) |
| Colorectal | 46 (3.11) | 37 (3.13) | 9 (3.05) |
| Esophageal | 44 (2.97) | 35 (2.96) | 9 (3.05) |
| Pancreatic | 35 (2.37) | 28 (2.36) | 7 (2.37) |
| Mesothelioma | 34 (2.30) | 27 (2.28) | 7 (2.37) |
| Ovarian | 31 (2.1) | 25 (2.11) | 6 (2.03) |
| Breast | 25 (1.69) | 20 (1.69) | 5 (1.69) |
| Drug class, n (%) | |||
| PD-1/PD-L1 | 1,221 (82.56) | 969 (81.84) | 252 (85.42) |
| CTLA-4 | 5 (0.33) | 5 (0.42) | 0 (0.00) |
| Combo | 253 (17.11) | 210 (17.74) | 43 (14.58) |
| ICB response, n (%) | |||
| Responder | 409 (27.65) | 319 (26.94) | 90 (30.51) |
| Non-responder | 1,070 (72.35) | 865 (73.06) | 205 (69.49) |
| Chemotherapy prior ICB, n (%) | |||
| No | 463 (31.30) | 370 (31.25) | 93 (31.53) |
| Yes | 1,016 (68.70) | 814 (68.75) | 202 (68.47) |
| Stage, n (%) | |||
| I-III | 97 (6.56) | 78 (6.59) | 19 (6.56) |
| IV | 1,382 (93.44) | 1,106 (93.41) | 276 (93.44) |
Combo, PD-1/PD-L1 plus CTLA-4; IQR, interquartile range; SCLC, small cell lung cancer.